DFTX Q4 2024 Earnings — Definium Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

DFTXDefinium Therapeutics, Inc.

$2B

Q4 2024 Earnings

Healthcare Medical - Pharmaceuticals

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$32M

Net Income

-$35M

EPS (Diluted)

$-0.41

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$25M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$302M

Total Liabilities

$61M

Stockholders' Equity

$241M

Cash & Equivalents

$274M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$32M	-$22M	-46.2%
Net Income	-$35M	-$24M	-45.6%